PURPOSE: In this longitudinal study, the cumulative incidence of patients with glaucoma and disc hemorrhages was investigated. A possible effect of glaucoma therapy on the incidence rate of disc hemorrhages was evaluated. METHODS: A group consisting of 68 patients with primary open-angle glaucoma (POAG), 34 with normal-pressure glaucoma, and 125 with suspected glaucoma (mean follow-up, 7.3 +/- 2.5 years; range 3-13 years) was observed closely with quarterly examinations. RESULTS: In normal-pressure glaucoma, the cumulative incidence of patients with disc hemorrhages was 35.3%, which was significantly higher than for those with POAG (10.3%; P < 0.01) and for those with suspected glaucoma (10.4%; P < 0.001). The mean follow-up period before a first disc hemorrhage was detected was 2.5 +/- 2.8 years. In the bleeders, recurrent disc hemorrhages were observed in 67% of the patients with normal-pressure glaucoma, 29% of those with POAG, and 54% of glaucoma suspects. In normal-pressure glaucoma, therapy had no effect on the incidence rate of disc hemorrhages. In glaucoma suspects, a significant reduction of the incidence rate of disc hemorrhages per year (0.11 +/- 0.04) was observed during episodes with therapy compared with episodes without (0.43 +/- 0.15; P < 0.05). A concept of two populations (i.e., one with disc hemorrhages and the other never having them) seems to be valid for normal-pressure glaucoma, but not for POAG and suspected glaucoma. CONCLUSION: The cumulative incidence of initial disc hemorrhages increases with time in POAG and suspected glaucoma, but reaches a limit in normal-pressure glaucoma. Glaucoma therapy may reduce the incidence rate of all, initial and recurrent, disc hemorrhages in patients with high pressures, but not in patients with normal-pressure glaucoma.
PURPOSE: In this longitudinal study, the cumulative incidence of patients with glaucoma and disc hemorrhages was investigated. A possible effect of glaucoma therapy on the incidence rate of disc hemorrhages was evaluated. METHODS: A group consisting of 68 patients with primary open-angle glaucoma (POAG), 34 with normal-pressure glaucoma, and 125 with suspected glaucoma (mean follow-up, 7.3 +/- 2.5 years; range 3-13 years) was observed closely with quarterly examinations. RESULTS: In normal-pressure glaucoma, the cumulative incidence of patients with disc hemorrhages was 35.3%, which was significantly higher than for those with POAG (10.3%; P < 0.01) and for those with suspected glaucoma (10.4%; P < 0.001). The mean follow-up period before a first disc hemorrhage was detected was 2.5 +/- 2.8 years. In the bleeders, recurrent disc hemorrhages were observed in 67% of the patients with normal-pressure glaucoma, 29% of those with POAG, and 54% of glaucoma suspects. In normal-pressure glaucoma, therapy had no effect on the incidence rate of disc hemorrhages. In glaucoma suspects, a significant reduction of the incidence rate of disc hemorrhages per year (0.11 +/- 0.04) was observed during episodes with therapy compared with episodes without (0.43 +/- 0.15; P < 0.05). A concept of two populations (i.e., one with disc hemorrhages and the other never having them) seems to be valid for normal-pressure glaucoma, but not for POAG and suspected glaucoma. CONCLUSION: The cumulative incidence of initial disc hemorrhages increases with time in POAG and suspected glaucoma, but reaches a limit in normal-pressure glaucoma. Glaucoma therapy may reduce the incidence rate of all, initial and recurrent, disc hemorrhages in patients with high pressures, but not in patients with normal-pressure glaucoma.
Authors: Swarup S Swaminathan; Amitabha S Bhakta; Wei Shi; William J Feuer; Alexandre R Abreu; Alejandro D Chediak; David S Greenfield Journal: J Glaucoma Date: 2018-01 Impact factor: 2.503
Authors: Donald L Budenz; Julia Beiser Huecker; Steven J Gedde; Mae Gordon; Michael Kass Journal: Am J Ophthalmol Date: 2016-11-07 Impact factor: 5.258
Authors: Huiyuan Hou; Sasan Moghimi; Linda M Zangwill; James A Proudfoot; Tadamichi Akagi; Takuhei Shoji; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Ophthalmol Glaucoma Date: 2019-11-14
Authors: Donald L Budenz; Douglas R Anderson; William J Feuer; Julia A Beiser; Joyce Schiffman; Richard K Parrish; Jody R Piltz-Seymour; Mae O Gordon; Michael A Kass Journal: Ophthalmology Date: 2006-09-25 Impact factor: 12.079
Authors: Tadamichi Akagi; Linda M Zangwill; Luke J Saunders; Adeleh Yarmohammadi; Patricia Isabel C Manalastas; Min Hee Suh; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Ophthalmology Date: 2017-05-09 Impact factor: 12.079